Talapro-3 could help move Talzenna into earlier prostate cancer.
ApexOnco Front Page
Recent articles
Single, double and even triple-payload ADCs will be presented at the meeting.
The latest clinical study listings reveal KRAS-targeting projects, ADCs and others starting phase 1.
Some light is shed on Dreamm-7, but precisely why this trial was successful remains a mystery.
Pelabresib's partial win at ASH was enough to persuade Novartis to pull the acquisition trigger.
Early-stage assets missing from the group’s pipeline include several ADCs, as the acquisition of ImmunoGen looms.
On a wing and a prayer AbbVie takes livmoniplimab into phase 3.
The end of three licensed assets sees Takeda take a step back from autologous cell therapy.